# US 2021/0330701 A1 · Methods and compositions for inhibiting enveloped viruses using high molecular weight hydrophobically modified alkali swellable emulsion polymers and surfactant > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2021/0330701 A1 - Document ID: US20210330701A1 - Status: Published application - Kind: A1 - Application number: 16/856,861 - Filed: 2020-04-23 - Published: 2021-10-28 - Earliest claimed: 2020-04-23 - Assignees: Johnson & Johnson Consumer Inc. - Applicants: Johnson & Johnson Consumer Inc. - Inventors: Elizabeth Bruning; Anthony Robert Geonnotti, III; Euen Thomas Ekman-Gunn; Russel Walters; Alpana Oak; Frank C. Sun; Kimberly Capone; Frank J. Kirchner - Web page: https://patentgrep.com/patent/US20210330701A1 ## CPC - A61K 31/78: of acrylic acid or derivatives thereof - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)} - A61K 31/085: having an ether linkage to aromatic ring nuclear carbon - A61K 31/765: Polymers containing oxygen - A61P 31/12: Antivirals - A61P 31/16: for influenza or rhinoviruses - A61P 31/18: for HIV - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract This invention relates to methods and compositions for inhibiting the transmission of enveloped viruses, which entails applying a composition containing a high molecular weight hydrophobically-modified polymer to an infectable or ingestible surface that may contain viruses and wherein said anti-viral composition comprises less than about 9% by weight of surfactant having an HLB greater than about 12. ## Claims ### Claim 1 A method of inhibiting entry of enveloped viruses into cells comprising contacting said viruses with an anti-viral composition comprising at least one high molecular weight hydrophobically modified polymer in an amount effective to inhibit entry of viruses into cells, wherein said anti-viral composition comprises less than about 9% by weight of surfactant having an HLB greater than about 12. ### Claim 2 (depends on 1) A method according to claim 1 wherein said composition comprises between about 0.375% and 9% by weight of surfactant. ### Claim 3 (depends on 2) A method according to claim 2 wherein said composition comprises between about 0.375% and 6% by weight of surfactant. ### Claim 4 (depends on 2) A method according to claim 2 wherein said composition comprises between about 0.375% and 3% by weight of surfactant. ### Claim 5 (depends on 1) A method according to claim 1 wherein the TEP of said anti-viral composition is greater than about 3.7. ### Claim 6 (depends on 1) A method according to claim 1 further comprising applying said anti-viral composition to infectable surfaces of a subject. ### Claim 7 (depends on 6) A method according to claim 6 wherein said infectable surfaces comprise one or more of the group consisting of skin and mucosal tissue of a subject. ### Claim 8 (depends on 7) A method according to claim 7 wherein said mucosal tissue comprises tissue selected from the group consisting of oral tissue, ocular tissue, nasal tissue, vaginal tissue, or rectal tissue and a combination thereof. ### Claim 9 (depends on 1) A method according to claim 1 wherein said the number average molecular weight (Mn) of said high molecular weight hydrophobically modified polymer is at least about 100,000 or more as measured by gel permeation chromatography (GPC) calibrated with a poly(methyl methacrylate) (PMMA) standard. ### Claim 10 (depends on 1) A method according to claim 1 wherein said high molecular weight hydrophobically modified polymer is a hydrophobicafly modified alkali swellable emulsion polymer selected from the group consisting of Acrylates/Steareth-20 Methacrylate Copolymer, Acrylates/Steareth-20 Methacrylate Crosspolymer, Acrylates/Ceteth-20 Itaconate Copolymer), Acrylates/Beheneth-25 Methacrylate Copolymer, hydrophobically modified anionic thickener and polyacrylate-33 and a combination thereof. ### Claim 11 (depends on 7) A method according to claim 7 wherein said high molecular weight hydrophobically modified polymer comprises polyacrylate-33. ### Claim 12 (depends on 1) A method according to claim 1 wherein said high molecular weight hydrophobically modified polymer is present in said composition in an amount of from about 0.00005% to about 3% percent by weight of the composition. ### Claim 13 (depends on 1) A method according to claim 1 wherein said composition further comprises at least 55% of water. ### Claim 14 (depends on 13) A method according to claim 13 wherein said composition comprises at least 97% of water. ### Claim 15 (depends on 1) A method according to claim 1 wherein said viruses are selected from the group consisting of poxviridae, herpesviridae, retroviridae Lentivirus and a combination thereof. ### Claim 16 (depends on 1) A method according to claim 1 wherein said virus selected from the family of herpesviridae is herpes simplex virus 1, herpes simplex virus 2 and a combination thereof. ### Claim 17 (depends on 16) A method according to claim 16 wherein said virus selected from the family retroviridae Lentivirus is Human Immunodeficiency Virus Type 1. ### Claim 18 (depends on 1) A method according to claim 1 wherein said inhibition of virus entry into said cells results in the reduction of potential for viral infection. ### Claim 19 (depends on 1) A method according to claim 1 wherein the anti-viral composition does not substantially disrupt biological surfaces. ### Claim 20 A method of inhibiting entry of enveloped viruses comprising contacting infectable surfaces with an anti-viral composition comprising at least one high molecular weight hydrophobically modified polymers in an amount effective to inhibit entry of viruses into cells, said anti-viral composition comprises less than about 9% by weight of surfactant having an HLB greater than about 12. ### Claim 21 (depends on 21) A method of inhibiting entry of enveloped viruses according to claim 21 further comprising contacting said viruses with said anti-viral composition. ### Claim 22 An anti-viral composition comprising at least one high molecular weight hydrophobically modified polymers in an amount effective to inhibit entry of viruses into cells and at least 55% water, wherein said anti-viral composition comprises less than about 9% by weight of surfactant having an HLB greater than about 12. ### Claim 23 An anti-viral composition comprising at least one high molecular weight hydrophobically modified polymers in an amount effective to inhibit entry of viruses into cells and at least 97% water, wherein said anti-viral composition comprises less than about 9% by weight of surfactant having an HLB greater than about 12. ### Claim 24 A method of inhibiting the transmission of viruses comprising applying to non-biological surfaces a composition comprising at least one high molecular weight hydrophobically modified polymer in an amount effective to inhibit entry of viruses into cells wherein said anti-viral composition comprises less than about 9% by weight of surfactant having an HLB greater than 12. ### Claim 25 A method of inhibiting the transmission of viruses comprising applying to ingestable surfaces a composition comprising at least one high molecular weight hydrophobically modified polymers in an amount effective to inhibit entry of viruses into cells wherein said anti-viral composition comprises less than about 9% by weight of surfactant having an HLB greater than 12. ### Claim 26 (depends on 1) A composition according to claim 1 wherein said composition comprises a dosage form selected from the group consisting of: a liquid, a lotion, a cream, a gel, a stick, a spray, a shaving cream, an ointment, a cleansing liquid wash, a solid bar, a shampoo, a paste, a powder, a mousse, a wipe, a patch, a wound dressing, an adhesive bandage, a hydrogel and a film. ### Claim 27 (depends on 9) A composition according to claim 9 wherein the number average molecular weight (Mn) of said high molecular weight hydrophobically modified polymer is at least about 100,000 or more as measured by gel permeation chromatography (GPC) calibrated with a poly(methyl methacrylate) (PMMA) standard. ### Claim 28 (depends on 28) A composition according to claim 28 wherein said hydrophobically modified high molecular weight polymer is a hydrophobically-modified alkali swellable emulsion polymer. ### Claim 29 (depends on 29) A composition according to claim 29 wherein said hydrophobically modified high molecular weight polymer comprises a hydrophobically modified alkali swellable emulsion polymer selected from the group consisting of: Acrylates/Steareth-20 Methacrylate Copolymer, Acrylates/Steareth-20 Methacrylate Crosspolymer, Acrylates/Ceteth-20 Itaconate Copolymer), hydrophobically modified anionic thickener and polyacrylate-33 and a combination thereof and a combination thereof. ### Claim 30 (depends on 30) A composition according to claim 30 wherein said hydrophobically modified high molecular weight polymer is polyacrylate-33. ### Claim 31 (depends on 1) A composition according to claim 1 wherein said composition further comprises nonoxynol-9.